Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
Healthtrust
Chubb
Cerilliant
Dow
Cantor Fitzgerald
McKesson
Harvard Business School

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ANAGRELIDE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Anagrelide Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00175838 Primary Thrombocythaemia 1 Trial Active, not recruiting Cambridge University Hospitals NHS Foundation Trust N/A The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.
NCT00175838 Primary Thrombocythaemia 1 Trial Active, not recruiting Institute of Cancer Research, United Kingdom N/A The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.
NCT00175838 Primary Thrombocythaemia 1 Trial Active, not recruiting University of Cambridge N/A The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.
NCT00202644 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed Shire Phase 4 Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to be produced. Platelets are small cells carried around in the blood, which help form blood clots. When patients have too many platelets, there is a risk of blood clots forming unnecessarily and excessive bleeding. The aim of this study is to gain additional information on the safety profile of Anagrelide (Xagrid(r)) and Hydroxyurea (also known as hydroxycarbamide).
NCT00413634 The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) Completed Shire Phase 2 Age related differences in response to a drug could arise from variation in pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles between age groups. Whilst the efficacy and safety profile of anagrelide is well established through a well-documented clinical trial programme in patients of all ages, no formal studies have been carried out to investigate whether the PK profile of anagrelide and its metabolites is altered with age. This study is designed to allow comparisons to be made in terms of pharmacokinetics of anagrelide and its metabolites between elderly (≥ 65 years) and young (18-50 years) ET patients
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Anagrelide Hydrochloride

Condition Name

Condition Name for Anagrelide Hydrochloride
Intervention Trials
Essential Thrombocythemia 5
Essential Thrombocythaemia 4
Healthy 3
High Risk Essential Thrombocythemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Anagrelide Hydrochloride
Intervention Trials
Thrombocytosis 16
Thrombocythemia, Essential 16
Polycythemia Vera 5
Polycythemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Anagrelide Hydrochloride

Trials by Country

Trials by Country for Anagrelide Hydrochloride
Location Trials
United States 52
Japan 18
Germany 11
France 7
Italy 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Anagrelide Hydrochloride
Location Trials
Pennsylvania 4
California 4
Arizona 4
North Carolina 4
Utah 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Anagrelide Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Anagrelide Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Anagrelide Hydrochloride
Clinical Trial Phase Trials
Completed 10
Recruiting 5
Active, not recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Anagrelide Hydrochloride

Sponsor Name

Sponsor Name for Anagrelide Hydrochloride
Sponsor Trials
Shire 5
AOP Orphan Pharmaceuticals AG 3
Roche Pharma AG 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Anagrelide Hydrochloride
Sponsor Trials
Industry 21
Other 12
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cerilliant
Cipla
Deloitte
Chubb
Fuji
Harvard Business School
QuintilesIMS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.